Absence of dopamine receptor serum autoantibodies in schizophrenia patients with an acute disease episode

Müller, Ulf; Teegen, Bianca; Probst, Christian; Bernstein, Hans‐Gert; Busse, Stefan; Bogerts, Bernhard; Schiltz, Kolja; Stoecker, Winfried; Steiner, Johann

doi:10.1016/j.schres.2014.06.025

Cited by 9 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the CBA we examined the presence of several known and unknown autoantibodies. In line with some prior studies we did not find autoantibodies against subunits of the NMDA-receptor (Masdeu et al, 2012;Rhoads et al, 2011) or subunits of the dopamine, AMPA and GABA receptor (Müller et al, 2014). However, there is still an ongoing debate about the presence of anti-NMDA receptor antibodies in patients with schizophrenia as some studies reported a seroprevalence of up to 10% (Hammer et al, 2014;Steiner et al, 2013).…”

Section: Discussionsupporting

confidence: 91%

“…Anti-brain antibodies were found to be increased in some studies but not in others, thoroughly reviewed elsewhere (Jones et al, 2005). The last decade, multiple studies have focused on the seroprevalence of autoantibodies targeting specific neuronal surface antibodies, such as NMDA (Pearlman and Najjar, 2014), dopamine, AMPA and GABA receptor antibodies (Ezeoke et al, 2013;Müller et al, 2014), with inconclusive evidence.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

No evidence for the presence of neuronal surface autoantibodies in plasma of patients with schizophrenia

Mierlo

Coevorden-Hameete

Munting

et al. 2015

European Neuropsychopharmacology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

No evidence for the presence of neuronal surface autoantibodies in plasma of patients with schizophrenia

Mierlo

Coevorden-Hameete

Munting

et al. 2015

European Neuropsychopharmacology

View full text Add to dashboard Cite

“…Knight postulates that the acute positive symptoms of schizophrenia are caused by auto-antibodies which interact with and stimulate dopamine receptors in certain neural pathways of the brain (dopamine-receptor-stimulating auto-antibodies) [ 21 ]. Despite the failure of some studies to detect dopamine receptor auto-antibodies in schizophrenia patients [ 22 , 23 ], the hypothesis of a major role of dopamine receptor serum antibodies is further supported by recent findings of an increased production of pro-inflammatory cytokines and auto-antibodies in acutely ill schizophrenia patients [ 24 , 25 ]. These antibodies would be analogous to the thyroid-stimulating auto-antibodies which cause the hyperthyroidism of Graves’ disease [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

HLA DRB1*03 as a possible common etiology of schizophrenia, Graves’ disease, and type 2 diabetes

et al. 2017

View full text Add to dashboard Cite

BackgroundAutoimmune diseases and schizophrenia share many common features. Association studies confirm a shared genetic association in the human leukocyte antigen (HLA) region between schizophrenia and most autoimmune diseases. To our knowledge, the simultaneous syndromes of Graves’ disease (GD) and type 2 diabetes (T2D) in schizophrenia are rare in Tunisia.Case presentationWe report a case of a 42-year-old woman admitted to the department of psychiatry for an acute relapse of chronic schizophrenia. Her medical history revealed that she was followed for Graves’ disease and for a type 2 diabetes mellitus. A low-resolution HLA typing was performed by polymerase chain reaction sequence-specific primer (PCR-SSP) techniques according to determine the patient’s haplotype.ConclusionsOur study suggests that the HLA DRB1*03 allele may explain a common etiology underlying the co-morbidity of Graves’ disease, type 2 diabetes, and schizophrenia in our patient.

show abstract

“…Whether these D2R antibodies stimulate the D2R has not yet been demonstrated, but this would be consistent with the now considerable evidence for dopaminergic overactivity in psychosis (Howes et al 2012 ). A large study of adults with schizophrenia experiencing an acute psychotic episode however failed to find D2R antibody positivity in this group (Muller et al 2014 ), although notably the CBA methodology differed considerably from the previous study.…”

Section: Dopamine Receptor Antibodiesmentioning

confidence: 63%

Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications

et al. 2015

View full text Add to dashboard Cite

Rationale Autoantibodies to central nervous system (CNS) neuronal surface antigens have been described in association with autoimmune encephalopathies which prominently feature psychiatric symptoms in addition to neurological symptoms. The potential role of these autoantibodies in primary psychiatric diseases such as schizophrenia or bipolar affective disorder is of increasing interest. Objectives We aimed to review the nature of psychiatric symptoms associated with neuronal surface autoantibodies, in the context of autoimmune encephalopathies as well as primary psychiatric disorders, and to review the mechanisms of action of these autoantibodies from a psychopharmacological perspective. Results The functional effects of the autoantibodies on their target antigens are described; their clinical expression is at least in part mediated by their effects on neuronal receptor function, primarily at the synapse, usually resulting in receptor hypofunction. The psychiatric effects of the antibodies are related to known functions of the receptor target or its complexed proteins, with reference to supportive genetic and pharmacological evidence where relevant. Evidence for a causal role of these autoantibodies in primary psychiatric disease is increasing but remains controversial; relevant methodological controversies are outlined. Non-receptor-based mechanisms of autoantibody action, including neuroinflammatory mechanisms, and therapeutic implications are discussed. Conclusions An analysis of the autoantibodies from a psychopharmacological perspective, as endogenous, bioactive, highly specific, receptor-targeting molecules, provides a valuable opportunity to understand the neurobiological basis of associated psychiatric symptoms. Potentially, new treatment strategies will emerge from the improving understanding of antibody-antigen interaction within the CNS.

show abstract

Absence of dopamine receptor serum autoantibodies in schizophrenia patients with an acute disease episode

Cited by 9 publications

References 16 publications

No evidence for the presence of neuronal surface autoantibodies in plasma of patients with schizophrenia

No evidence for the presence of neuronal surface autoantibodies in plasma of patients with schizophrenia

HLA DRB1*03 as a possible common etiology of schizophrenia, Graves’ disease, and type 2 diabetes

Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications

Contact Info

Product

Resources

About